Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

Rhea-AI Summary

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) to present at the 7th Obesity & NASH Drug Development Summit on the use of AI/ML and Multi-Omics for Clinical NASH Study Enrichment

EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it will present at the 7^th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston.

Scott Campbell, PhD, Hepion’s Quantitative Translational Pharmacologist, will deliver an oral presentation on the use of AI / machine learning (“ML”) to enrich NASH clinical trials and for NASH patient selection; and the use of multi-omics with ML for biomarker response prediction.

Presentation details:

Title:	Using AI/ML and Multi-Omics to Determine Efficacy for Clinical NASH Study Enrichment: Highlights from Recently Completed Phase 2 Trials with Rencofilstat
Presenter:	Dr. Scott Campbell
Session:	Track B: Clinical, Regulatory & Outcomes
Date:	Wednesday, November 29, 2023
Time:	11:00 a.m. ET

About Hepion Pharmaceuticals

The Company’s lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models and is currently in Phase 2 clinical development for the treatment of NASH. In November 2021, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for rencofilstat for the treatment of NASH. That was followed in June 2022 by the FDA’s granting of Orphan Drug designation to rencofilstat for the treatment of HCC.

Hepion has created a proprietary Artificial Intelligence deep machine learning (“AI/ML”) platform designed to better understand disease processes and identify patients that are rencofilstat responders. This AI/ML has the potential to shorten development timelines and increase the observable differences between placebo and treatment groups. In addition, Hepion’s AI/ML can be used to drive its ongoing NASH and HCC clinical development programs and identify other potential therapeutic indications for cyclophilin inhibition with rencofilstat.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com  

What is the company name and ticker symbol of the biopharmaceutical company presenting at the 7th Obesity & NASH Drug Development Summit?

The company is Hepion Pharmaceuticals, Inc. and its ticker symbol is NASDAQ:HEPA.

What is the focus of Hepion Pharmaceuticals, Inc. in terms of therapeutic drug development?

Hepion Pharmaceuticals, Inc. is focused on AI-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases.

Who will be delivering the oral presentation at the summit and on what topic?

Dr. Scott Campbell, Hepion's Quantitative Translational Pharmacologist, will deliver a presentation on the use of AI/ML to enrich NASH clinical trials and for NASH patient selection, as well as the use of multi-omics with ML for biomarker response prediction.

When and where will the presentation take place?

The presentation will take place on Wednesday, November 29, 2023, at 11:00 a.m. ET at the 7th Obesity & NASH Drug Development Summit in Boston.